Loading…
Hemab Therapeutics Holdings, Inc. is projected to rise to $56.15 by 2027, a +48% move from its current price of $38.03. Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $35.52 | $38.07 | $40.81 | +0.11% |
| Jul 15 | $34.55 | $38.12 | $42.04 | +0.22% |
| Jul 16 | $33.84 | $38.16 | $43.03 | +0.34% |
| Jul 17 | $33.25 | $38.20 | $43.89 | +0.45% |
| Jul 18 | $32.75 | $38.24 | $44.66 | +0.56% |
| Jul 19 | $32.30 | $38.29 | $45.38 | +0.67% |
| Jul 20 | $31.90 | $38.33 | $46.05 | +0.79% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.90 | $38.33 | $46.05 | +0.79% |
| Week 2 | $29.80 | $38.63 | $50.08 | +1.58% |
| Week 3 | $28.33 | $38.94 | $53.50 | +2.38% |
| Week 4 | $27.19 | $39.24 | $56.64 | +3.19% |
| Week 5 | $26.24 | $39.55 | $59.62 | +4.00% |
| Week 6 | $25.43 | $39.86 | $62.49 | +4.82% |
| Week 7 | $24.72 | $40.18 | $65.29 | +5.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on therapies that address blood coagulation disorders to sustain life and human resilience in the United States of America and Denmark. Its products include HMB-001, a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and HMB-002, a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.
The company was founded in 2020 and is based in Cambridge, Massachusetts.
Hemab Therapeutics Holdings, Inc. (COAG) operates in the Healthcare sector as a clinical-stage biotechnology company developing therapies for blood coagulation disorders. The current price is $37.20 per share, with a market capitalization of $1.74B, and it ranks 2167 in market positioning.
A major floor 45.8% below — a decisive break under it would weaken the trend.
The nearest floor, 34.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 22.9% above — clearing it would confirm fresh momentum.
Key COAG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COAG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.12 | Buy | $35.33 | Buy |
| MA 10 | $33.99 | Buy | $33.69 | Buy |
| MA 20 | $30.77 | Buy | $31.79 | Buy |
| MA 50 | — | Neutral | — | Neutral |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.27 | Neutral |
| Stoch RSI (14) | 86.82 | Sell |
| CCI (20) | 142.53 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.70 | Buy |
| ROC (12) | 30.46 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 4.99 | Buy |
| Ultimate (7,14,28) | 58.16 | Neutral |
| Momentum (10) | 10.31 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 36.11 | Buy |
| ADX (14) | 18.97 | Neutral |
| ATR (14) | 1.77 | Info |
The near-term technical picture is bullish, with sentiment labeled BULLISH and an RSI of 60. The 30-day range runs from $23.18 to $59.70, giving a near-term perspective on volatility and price movement. The stock shows a defined near-term support at $24.98 and a near-term resistance at $37.20.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $24.98 | $38.03 | $72.53 | 0% | Neutral | |
| $36.70 | $56.15 | $92.92 | +48% | Bullish | |
| $41.38 | $70.21 | $126.50 | +85% | Bullish | |
| $37.96 | $70.65 | $135.67 | +86% | Bullish | |
| $38.94 | $79.06 | $159.94 | +108% | Bullish | |
| $52.48 | $116.00 | $245.28 | +205% | Bullish | |
| $63.14 | $140.31 | $308.44 | +269% | Bullish | |
| $79.74 | $177.20 | $403.23 | +366% | Bullish | |
| $90.55 | $201.22 | $462.80 | +429% | Bullish | |
| $76.77 | $170.59 | $392.36 | +349% | Bullish | |
| $161.46 | $358.80 | $825.24 | +843% | Bullish | |
| $424.41 | $943.13 | $2,169.20 | +23.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $24.98 | $38.03 | $50.25 | +0.00% |
| August 2026 | $33.18 | $41.26 | $54.07 | +8.49% |
| September 2026 | $33.13 | $42.12 | $56.90 | +2.10% |
| October 2026 | $36.03 | $46.69 | $64.66 | +10.84% |
| November 2026 | $38.32 | $50.48 | $71.35 | +8.12% |
| December 2026 | $37.66 | $50.38 | $72.53 | -0.21% |
Click any year to see its month-by-month COAG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, COAG could reach as high as $72.53, with a base case around $38.03 and support toward $24.98 — roughly 0% from $38.03. A consolidation phase looks the most probable path here.
Expect COAG to range from $36.70 to $92.92 through 2027. The $56.15 average target implies a +48% move from current prices. That is up +48% on the projected 2026 average. Momentum favours further upside here.
The COAG price prediction for 2028 points to an average of $70.21 (low $41.38, high $126.50) — a potential gain of +85% on today's $38.03. Buyers look set to stay in control over this stretch.
In 2029, COAG is projected to trade between $37.96 and $135.67, averaging $70.65 — a potential gain of +86% from today's $38.03. That is up +1% on the projected 2028 average. Momentum favours further upside here.
Hemab Therapeutics Holdings, Inc.'s 2030 outlook centres on $79.06, within a $38.94 to $159.94 range. That is up +12% on the projected 2029 average. That marks a +108% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, COAG could reach as high as $245.28, with a base case around $116.00 and support toward $52.48 — roughly +205% from $38.03. Momentum favours further upside here.
Expect COAG to range from $63.14 to $308.44 through 2032. The $140.31 average target implies a +269% move from current prices. That is up +21% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The COAG price prediction for 2033 points to an average of $177.20 (low $79.74, high $403.23) — a potential gain of +366% on today's $38.03. Momentum favours further upside here.
In 2034, COAG is projected to trade between $90.55 and $462.80, averaging $201.22 — a potential gain of +429% from today's $38.03. That is up +14% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Hemab Therapeutics Holdings, Inc.'s 2035 outlook centres on $170.59, within a $76.77 to $392.36 range. That is -15% versus the projected 2034 average. That marks a +349% change versus current levels. Momentum favours further upside here.
By 2040, COAG could reach as high as $825.24, with a base case around $358.80 and support toward $161.46 — roughly +843% from $38.03. Buyers look set to stay in control over this stretch.
Expect COAG to range from $424.41 to $2,169.20 through 2050. The $943.13 average target implies a +23.8x move from current prices. That is up +163% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in COAG today (≈ 26.29503 COAG) could be worth
$24,799.69
+$23,799.69 (+2380%) by 2050 · US Dollar
Based on the average projected COAG price of $943.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COAGwould be worth at today's price.
$1,000 invested in COAG on May 1, 2026 (≈ 29.411765 COAG) would be worth
$1,118.53
+$118.53 (+11.9%) today · 1.12× · US Dollar
Based on a COAG entry price of $34 vs. today's $38.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31 | $1,226.77 | +22.7% |
| 1 month ago | $25.55 | $1,488.45 | +48.8% |
| All time ago | $34 | $1,118.53 | +11.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COAG forecast.
Our base-case forecast reaches $76.00 around 2030.
Implied market cap at $76.00: $3.55B
The multi-year forecast depicts a bullish trajectory beyond 2026. In 2027 the average price is $56.22 with a max of $93.11 and an ROI of 51.1%; in 2028 the average is $70.13 with a max of $126.42 and an ROI of 88.5%; in 2029 the average is $70.57 with a max of $135.58 and an ROI of 89.7%; in 2030 the average is $79.00 with a max of $159.88 and an ROI of 112.4%. Looking further out, the forecast shows 2040 with an average of $358.56, a max of $824.69 and an ROI of 863.9%, and 2050 with an average of $926.08, a max of $2,129.98 and an ROI of 2389.4%.
Across these years, sentiment remains BULLISH, reflecting substantial upside potential, while noting these are estimates and not guarantees.
Tap a question to reveal the answer.
2030 min $38.88, avg $79.00, max $159.88, ROI 112.4%, sentiment BULLISH.
The forecast shows a bullish path from 2027 onward with rising averages and ROI: 2027 avg $56.22 (ROI 51.1%), 2028 avg $70.13 (ROI 88.5%), 2029 avg $70.57 (ROI 89.7%), 2030 avg $79.00 (ROI 112.4%), culminating in 2040 avg $358.56 (ROI 863.9%) and 2050 avg $926.08 (ROI 2389.4%). These are estimates, not guarantees.
Yes. The 2028 max is $126.42, and the 2030 max is $159.88, indicating the possibility of surpassing $100 by 2028 or 2030 based on the forecast.
2040 has an average of $358.56 and a max of $824.69 (ROI 863.9%), while 2050 shows an average of $926.08 and a max of $2,129.98 (ROI 2389.4%). The sentiment remains BULLISH, pointing to substantial upside over the long term.
The current price is $37.20 per share and the market cap is $1.74B; the rank is 2167.
Hemab Therapeutics Holdings, Inc. Community Discussion
0Share your Hemab Therapeutics Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.